Trulieve: Analysts Expect Beat On Company Full Year Guidance

Trulieve Cannabis (CSE: TRUL) announced that they will be reporting their fourth quarter and year-end financials pre-market on March 23rd. Analysts have a consensus C$65.83 12-month price target on the company, via a total of 14 analysts, with two analysts have strong buy ratings and the other 12 have buy ratings. The street high comes from Stifel-GMP with a C$107 price target, and the lowest target comes from Echelon Wealth with a C$43 price target.

Twelve analysts have revenue estimates for the fourth quarter. The mean between all 12 is U$162.49 million; this number has been revised upwards from U$159.35 million at the start of the year. Stifel-GMP currently has the highest revenue estimate with U$170.87 million, while the lowest comes from PI Financial with a U$153.25 estimate.

For the full year, management has guided for revenues between U$465 – U$485 million, but the average estimate between 14 analysts is currently U$513.59 million. This number has been revised upwards from U$511.55 million at the start of the year. The street high comes from Stifel-GMP with a U$523.95 full-year revenue estimate.

Onto EBITDA estimates, there are currently 12 analysts who have fourth-quarter EBITDA estimates. The mean is currently U$75.56 million, with this number being revised upwards from U$72.46 million at the start of the year. Street high goes to Needham with a U$81.30 million EBITDA estimate and the lowest being PI Financial with a U$68.87 million estimate.

For the full-year management has also provided guidance for EBITDA in the range of U$205 – U$225 million. The current EBITDA means across 13 analysts is U$252.47 million, with that number basically staying flat year-to-date. Needham currently has the highest full-year estimate at U$258.80 million.

Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Leave a Reply